Adverum Biotechnologies, Inc.: Nasdaq/NYSE listing notice — Adverum transfers to Nasdaq Capital Market; gets Nov 13 deadline for $1 bid compliance

Adverum Biotechnologies, Inc.

Approved transfer from Nasdaq Global Market to Capital Market, effective May 22, 2023.
Granted additional 180-day grace period until November 13, 2023 to regain $1.00 minimum bid price.
Must have closing bid price at least $1.00 for ten consecutive business days during grace period.
Plans reverse stock split to regain compliance; proxy statement filed for shareholder vote.
Failure to comply by Nov 13 may lead to delisting and trading on OTC markets.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Adverum Biotechnologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

May 18, 2023, the Company received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s securities will be transferred to the Capital Market at the opening of business on May 22, 2023. The Company’s common stock will continue to trade under the symbol “ADVM.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-149306

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.